News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab
Maite Bourlon/ascopubs.org
Mar 2, 2025, 14:36

Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab

Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute of Medical Sciences and Nutrition Salvador Zubirán, shared a post on X:

“How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab?

  • Lack of evidence and need trials
  • Look at proposed algorithm
  • Ongoing trials mUC after EV and ICIs
  • Table of efficacy outcomes of platinum, erdafitinib (FGFR3) and trastu deruxtecan.”

“Optimizing Treatment Strategies for Advanced Urothelial Cancer: What Comes After Frontline Enfortumab Vedotin and Pembrolizumab?”

Authors: Maria Bourlon, Paola Valdez, Thomas Powles, Thomas Flaig.

Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab

More posts featuring Maite Bourlon.

cancer Enfortumab vedotin Maite Bourlon metastastic urothelial carcinoma OncoDaily Oncology Paola Valdez pembrolizumab Thomas Flaig Thomas Powles
Special Coverage
Career
Apr 1, 2025, 14:57
Sharon Burk completes PhD with groundbreaking research - Sbarro Health Research Organization
Opinion
Apr 1, 2025, 14:35
Douglas Flora: The messy truth behind healthcare's coming AI adoption
Blog
Apr 1, 2025, 14:31
Zainab Shinkafi-Bagudu: Processed meats and fried snacks may increase the risk of colorectal cancer
Societies
Apr 1, 2025, 14:08
Myeloma Paper of the Day, April 1st, suggested by Robert Orlowski
Blog
Apr 1, 2025, 12:54
CTOS Communications Committee: Survey to understand your engagement with social media
Science
Apr 1, 2025, 12:48
Yan Leyfman: Dual-Targeted CAR-T Therapy Shows 100% Response in MCL
Blog
Apr 1, 2025, 12:43
By 2040, the global burden of colorectal cancer is expected to rise by 63% - Digestive Cancers Europe
Blog
Apr 1, 2025, 12:34
Asya Agulnik: Breakthrough approaches needed for pediatric cancer treatment in conflict-affected regions
Blog
Apr 1, 2025, 12:18
What if 'No Response' Becomes 'No Recurrence' in Colorectal Cancer Treatment? - CancerWorld
Blog
Apr 1, 2025, 12:16
Maryam S. Yazdy: From FDA to BeiGene - Embracing a New Chapter
Blog
Apr 1, 2025, 12:13
Mehmet Murat Zerey: Hypofractionated Radiotherapy for Soft Tissue Sarcomas
Blog
Apr 1, 2025, 12:07
Iyad Sultan: Language models struggle with the spatial understanding of human anatomy